Disclaimer Semaglutide is the United States Adopted Name (USAN) for a research peptide compound
GLP-1 access in India is shaped by three layers: patent timing, regulatory approvals, and the ability of Indian companies to manufacture high-quality peptide and biologic-like products at scale.[5] 2.1 How Indian Patent Law Shapes GLP-1 Access Under Indian patent law, drug molecules get 20-year protection from the date of filing, but only for truly novel inventions, not for minor tweaks
GPX3 can use glutathione as an excellent substrate to participate in the redox reactions involved in glutathione and NADPH (Figure 1)
Mahyar Etminan, an epidemiologist and CEO of Epilytics in Vancouver, British Columbia, Canada
This led to the identification of exendin-4, the compound that inspired todays GLP-1 receptor agonists
Cell Proliferation, 54 (3), Article e12997